IP Library Granted Patent US 7,919,089
Granted Patent B2
US 7,919,089 · App. 10/554,851 · Granted Apr 5, 2011

Pharmaceutical composition comprising a bispecific antibody for EpCAM

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,919,089
App. No.
10/554,851
Granted
Apr 5, 2011
Kind
B2
Abstract

The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.

Claims (9)

1. A pharmaceutical composition comprising a bispecific single chain antibody construct comprising at least two domains, wherein one of the domains binds to human EpCAM antigen and the second domain binds to human CD3 antigen and wherein said bispecific single chain antibody construct comprises an amino acid sequence selected from the group of

(a) an amino acid sequence as shown in SEQ ID NO: 44;

(b) an amino acid sequence encoded by a nucleic acid sequence as shown in SEQ ID NO: 43; and

(c) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence as shown in SEQ ID NO: 43.

2. A kit comprising a pharmaceutical composition as defined in claim 1 .

3. A bispecific single chain antibody construct comprising at least two domains, wherein one of the domains binds to human EpCAM antigen and the second domain binds to human CD3 antigen and wherein said bispecific single chain antibody construct comprises an amino acid sequence selected from the group of:

(a) an amino acid sequence as shown in SEQ ID NO: 44;

(b) an amino acid sequence encoded by a nucleic acid sequence as shown in SEQ ID NO: 43; and

(c) an amino acid sequence encoded by a nucleic acid sequence which is degenerate as a result of the genetic code to a nucleotide sequence as shown in SEQ ID NO: 43.

Assignments (2)
CHANGE OF NAME Recorded Apr 10, 2013
From: MICROMET AG
To: AMGEN RESEARCH (MUNICH) GMBH
Reel/Frame 030187/0309 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2006
From: KUFER, PETER; BERRY, MEERA; OFFNER, SONJA; BRISCHWEIN, KLAUS; WOLF, ANDREAS; RAUM, TOBIAS; KOHLEISEN, BIRGIT; LENKKERI-SCHUTZ, ULLA; BAUERLE, PATRICK
To: MICROMET AG
Reel/Frame 017790/0409 →